IL32 has been shown to support tumor suppression in transgenic mice inoculated with melanoma and colon cancer cells [37] and up-regulated in lung adenocarcinomas [38] where it is considered a potential clinical target. This evidence concerns the gene IL32 and colonic neoplasm.